Document 3121
 DOCN  M94A3121
 TI    HIV-1 infection and liver disease in IDUs.
 DT    9412
 AU    Miguez-Burbano MJ; Lu Y; Page B; Gregory M; Fletcher MA; Quesada J;
       Shor-Posner G; Baum MK; Dept of Epidemiology, University of Miami School
       of Medicine, FL.
 SO    Int Conf AIDS. 1994 Aug 7-12;10(1):149 (abstract no. PB0021). Unique
       Identifier : AIDSLINE ICA10/94369454
 AB    OBJECTIVE: As liver disease is frequently observed in intravenous drug
       users (IDUs), the clinical significance of liver dysfunction in HIV
       disease, and its relationship to immune activation, serum protein and
       lipid profiles, was determined in HIV-1 seropositive and seronegative
       IDUs. METHODS: Liver function tests (GGT, GOT), immune activation (beta
       2-microglobulin, B2M), serum protein (total protein, albumin and
       globulin) and lipid profiles (serum choelesterol, triglycerides), were
       evaluated in 30 HIV+, asymptomatic IDUs (mean CD4 440 +/- 283) and 40
       seronegative IDUs (mean CD4 961 +/- 353). RESULTS: Elevated liver
       enzymes were observed in 35% of the HIV- and 50% of the HIV+ subjects.
       Levels of GOT were significantly higher in the seropositives (67.3 +/-
       55.3) relative to the seronegatives (p < 0.05). The HIV-1+ IDUs also
       exhibited increased immune activation (B2M 4.31 +/- 1.6) as well as
       levels of serum triglycerides (153.7 +/- 37) and globulins (4.45 +/-
       1.0); hypocholesterolemia (< 150 mg/dl) was observed in 40% of the HIV
       seropositives and 28% of the seronegatives. Abnormal liver function in
       HIV+ patients was associated with significantly higher levels of
       triglycerides (185.9 +/- 106.6 vs 111.6 +/- 58.9, p = 0.05) and
       cholesterol (174.2 +/- 39.2 vs 133 +/- 40.9 p < 0.02), as compared to
       HIV+ IDUs with normal liver enzymes; proteins and B2M were similar in
       the groups with and without abnormal liver function. DISCUSSION AND
       CONCLUSIONS: Liver dysfunction in IDUs may intensify the impact of HIV
       infection on lipid status, but does not appear to affect the level of
       serum proteins or immune activation.
 DE    beta 2-Microglobulin/ANALYSIS  Acquired Immunodeficiency
       Syndrome/*PHYSIOPATHOLOGY  Aspartate Aminotransferase/BLOOD  Blood
       Proteins/ANALYSIS  Cholesterol/BLOOD  Comparative Study
       Gamma-Glutamyltransferase/BLOOD  Human  HIV Seronegativity/*PHYSIOLOGY
       HIV Seropositivity/*PHYSIOPATHOLOGY  HIV-1/*ISOLATION & PURIF  *Liver
       Function Tests  *Substance Abuse, Intravenous  Triglycerides/BLOOD
       MEETING ABSTRACT

       SOURCE: National Library of Medicine.  NOTICE: This material may be
       protected by Copyright Law (Title 17, U.S.Code).